Evidence mapPaperPMID 41559842Full record

ArticleActa neuropathologica communications2026

Brain and circulating EV proteome signatures in schizophrenia as prognostic markers for age-related dementia.

Jose Antonio Sánchez Milán, Maria Mulet, Itziar Molet, Julia Lisa-Molina, Maria Font-Alberich, Cristina Lorca, Montserrat Gea-Sánchez, Filip Bellon, Iolanda Batalla, J Javier Meana and 6 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jose Antonio Sánchez Milán *Lleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain.
Maria Mulet *Lleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain.
Itziar Molet *Lleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain.
Julia Lisa-MolinaLleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain.
Maria Font-AlberichLleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain.
Cristina LorcaLleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain.
Montserrat Gea-SánchezHealthcare Research Group, Institute of Biomedical Research in Lleida (IRBLleida), Lleida, Spain.
Filip BellonHealthcare Research Group, Institute of Biomedical Research in Lleida (IRBLleida), Lleida, Spain.
Iolanda BatallaPsychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198, Lleida, Spain.
J Javier MeanaDepartment of Pharmacology, University of the Basque Country UPV/EHU, 48940, Leioa, Spain.
Luis F CalladoBioBizkaia Health Research Institute, 48903, Barakaldo, Spain.
Benito MorentinBasque Institute of Legal Medicine, Bilbao, Spain.
Alfredo Ramos-MiguelDepartment of Pharmacology, University of the Basque Country UPV/EHU, 48940, Leioa, Spain.
Raj N KalariaTranslational and Clinical Research Institute, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.
Aida Serra *Department of Medical Basic Sciences (CMB), +Pec Proteomics Research Group (+PPRG), Biomedical Research Institute of Lleida - (IRBLLEIDA), University of Lleida (UdL), 80, Av. Rovira Roure, 25198, Lleida, Spain. aida.serra@udl.cat.
Xavier Gallart-Palau *Lleida Institute of Biomedical Research Foundation Dr. Pifarré: Institut de Recerca Biomedica de Lleida Fundació Dr. Pifarré (IRBLLEIDA) - +Pec Proteomics Research Group (+PPRG) - Neuroscience Area, University Hospital Arnau de Vilanova (HUAV), 80, Av. Rovira Roure, 25198, Lleida, Spain. xgallart@irblleida.cat.

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2022 DI 100Agència de Gestió d'Ajuts Universitaris i de Recerca 2023 LLAV 00056Agencia Estatal de Investigación PID2020-114885RB-C21Diputació de Lleida, Spain PIRS22/03Diputació de Lleida, Spain PIRS23/02Eusko Jaurlaritza IT1512/22Instituto de Salud Carlos III PI22/00443NextGenerationEU PRTR-C17.I1Universitat de Lleida X25022
6 · The paper itself

Abstract

Schizophrenia (SZ) is epidemiologically linked to an increased risk of developing age-related dementias (ARD) predominantly characterized by Alzheimer's disease and vascular dementia. However, the molecular mechanisms underlying this association remain insufficiently elucidated. Extracellular vesicles (EVs) play a critical role in neuropathological processes and offer a promising avenue for identifying shared disease mechanisms and potential circulating markers for patient stratification. Here we used a two-phase systems biology approach integrating discovery-driven proteomics with a targeted validation strategy using data-independent acquisition mass spectrometry (DIA-MS) in a large, independent SZ cohort. First, we analyzed brain-derived EVs (bEVs) from post-mortem SZ and ARD subjects to identify shared molecular signatures. Next, we validated the presence and circulation of these bEV markers in circulating plasma EVs (pEVs) using DIA-MS data. Remarkably, SZ and ARD bEV proteome and peptidome showed overlapping alterations in neuronal connectivity, synaptic integrity, neuroinflammation, and metabolism. Unsupervised clustering analysis of correlated bEV/pEV markers stratified SZ patients into two clusters: high dementia risk and control-like profiles. Collectively, these data emphasize the significance of bEVs as crucial mediators of shared neuropathogenic mechanisms in SZ, and ARD. Furthermore, we identified a set of pEVs markers, including proteins and specific peptides, with a robust and promising bench-to-bedside trajectory that may facilitate the stratification of SZ patients at risk for ARD.

Indexed as

BrainDementiaExtracellular VesiclesProteomeSchizophreniaAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosisProteomicsBiomarkersProteomeAlzheimer’s diseaseBiomarker discoveryDementia risk stratificationExtracellular vesiclesProteomicsSchizophreniaTranslational neuroscienceVascular dementia

Identifiers

PMID41559842
PMCPMC12905883

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.